GE Healthcare said initial results from two Phase III trials are promising for flutemetamol, an experimental PET imaging agent for Alzheimer's disease. In one study, findings on PET correlate with brain-autopsy data. In the other study, results are consistent with a known lack of brain amyloid in patients.

Related Summaries